Staff Members - Benha University
Pre‑treatment serum inflammatory cytokines as survival predictors of patients with nasopharyngeal carcinoma receiving chemoradiotherapy
• 2016
Publication Information
Authors
ADEL F. AL-KHOLY, OMMINEA A. ABDULLAH, MAMDOUH Z. ABADIER, MANAL M. HASSAAN, MOHAMED F. SHINDY, DALIA M. NOR EL-DIEN and ALI HASANEEN
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Abstract. The present study aimed to examine the predictability
of pre-treatment serum levels of interleukin (IL)-1β, IL-6 and
tumor necrosis factor (TNF)-α for determining the outcome
of patients with nasopharyngeal carcinoma (NPC) assigned
for chemoradiotherapy. A total of 35 patients with NPC were
subjected to clinical examination and evaluation of performance
status
using
Karnofsky
scoring.
Nasopharyngoscopy
was
performed
for
evaluation
and
to
obtain
a biopsy.
Blood
samples
were
obtained
pre-
and
post-treatment
for
polymerase
chain
reaction
quantitative
estimation
of
Epstein-Barr
virus
(EBV)
DNA
plasma
load
and
enzyme-linked
immunosorbent
assay
for
estimation
of
serum
cytokines.
All
patients
received
chemoradiotherapy
and
were
followed-up
for
2
years.
Cervical
lymphadenopathy
and
recurrent
attacks
of
epistaxis
are
the
most
common presenting symptoms. Treatment significantly
decreased pre-treatment plasma EBV DNA load and serum
levels of IL-6 and TNF-α, and increased serum IL-1β levels.
Clinical staging and EBV DNA plasma load revealed positively
significant correlation with pre‑treatment serum levels of both
IL-6 and TNF-α, while revealed negative significant correlation
with
serum
IL-1β
levels.
The
2-year
survival
rate
was
negatively
significantly correlated with pre‑treatment levels of
IL-6 and TNF-α, and EBV DNA viral load, while it was positively
significantly correlated with pre‑treatment performance
of pre-treatment serum levels of interleukin (IL)-1β, IL-6 and
tumor necrosis factor (TNF)-α for determining the outcome
of patients with nasopharyngeal carcinoma (NPC) assigned
for chemoradiotherapy. A total of 35 patients with NPC were
subjected to clinical examination and evaluation of performance
status
using
Karnofsky
scoring.
Nasopharyngoscopy
was
performed
for
evaluation
and
to
obtain
a biopsy.
Blood
samples
were
obtained
pre-
and
post-treatment
for
polymerase
chain
reaction
quantitative
estimation
of
Epstein-Barr
virus
(EBV)
DNA
plasma
load
and
enzyme-linked
immunosorbent
assay
for
estimation
of
serum
cytokines.
All
patients
received
chemoradiotherapy
and
were
followed-up
for
2
years.
Cervical
lymphadenopathy
and
recurrent
attacks
of
epistaxis
are
the
most
common presenting symptoms. Treatment significantly
decreased pre-treatment plasma EBV DNA load and serum
levels of IL-6 and TNF-α, and increased serum IL-1β levels.
Clinical staging and EBV DNA plasma load revealed positively
significant correlation with pre‑treatment serum levels of both
IL-6 and TNF-α, while revealed negative significant correlation
with
serum
IL-1β
levels.
The
2-year
survival
rate
was
negatively
significantly correlated with pre‑treatment levels of
IL-6 and TNF-α, and EBV DNA viral load, while it was positively
significantly correlated with pre‑treatment performance